Gan & Lee Pharmaceuticals reported favorable Phase 1 outcomes for its oral GLP-1 receptor agonist, GZR18 tablet, in healthy subjects, showing a weight loss of 4.16% over two weeks.
New BLA for Datopotamab Deruxtecan filed in the U.S. for fast-track approval in patients with advanced EGFR-mutated non-small cell lung cancer who have received prior treatment.
Autolus Therapeutics has received FDA approval for AUCATZYL® (obecabtagene autoleucel-obe-cel) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).